Feigin VL, Vos T. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–97.
Article
Google Scholar
Coleman ER, Moudgal R, Lang K, Hyacinth HI, Awosika OO, Kissela BM, et al. Early rehabilitation after stroke: a narrative review. Curr Atheroscler Rep. 2017;19(12):59.
Article
PubMed
PubMed Central
Google Scholar
Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, et al. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010;58(7):987–1001.
Article
CAS
PubMed
Google Scholar
Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, Widmann C, et al. MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology. 2011;61(4):622–31.
Article
CAS
PubMed
Google Scholar
Venketasubramanian N, Kumar R, Soertidewi L, Bakar AA, Laik C, Gan R. The NeuroAiD safe treatment (NeST) registry: a protocol. BMJ Open. 2015;5(11):1–7.
Article
Google Scholar
Siddiqui FJ, Venketasubramanian N, Chan ESY, Chen C. Efficacy and safety of MLC601 (NeuroAiD®), a traditional chinese medicine, in poststroke recovery: a systematic review. Cerebrovasc Dis. 2013;35(Suppl 1):8–17.
Article
PubMed
Google Scholar
Navarro JC, Molina MC, Baroque AC II, Lokin JK. The use of NeuroAiD (MLC601) in postischemic stroke patients. Rehabil Res Pract. 2012. https://doi.org/10.1155/2012/506387.
Article
PubMed
PubMed Central
Google Scholar
Huang S, Lin M, Pan X, Tan Q, Tan K-L. The potential of MLC901 (NeuroAiD IITM), a traditional Chinese medicine. Neurosci Res Notes. 2019;2(2):18–24.
Article
Google Scholar
Muscari A, Collini A, Fabbri E, Giovagnoli M, Napoli C, Rossi V, et al. Changes of liver enzymes and bilirubin during ischemic stroke: mechanisms and possible significance. BMC Neurol. 2014;14(1):1–8.
Article
Google Scholar
Ruban A, Daya N, Schneider ALC, Gottesman R, Selvin E, Coresh J, et al. Liver enzymes and risk of stroke: the atherosclerosis risk in communities (aric) study. J Stroke. 2020;22(3):357–68.
Article
PubMed
PubMed Central
Google Scholar
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.
Article
PubMed
Google Scholar
Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708–18.
Article
PubMed
PubMed Central
Google Scholar
Widmann C, Gandin C, Petit-Paitel A, Lazdunski M, Heurteaux C. The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia. Sci Rep. 2018;8(1):1–15.
Article
Google Scholar
Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, et al. NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovasc Dis. 2013;35:1–7.
Article
PubMed
Google Scholar
Chan HYA, Stanton LW. A pharmacogenomic profile of human neural progenitors undergoing differentiation in the presence of the traditional Chinese medicine NeuroAiD. Pharmacogenomics J. 2016;16(5):461–71.
Article
CAS
PubMed
Google Scholar
Navarro JC, Gan HH, Lao AY, Baroque AC, Hiyadan JH, Chua CL, CHIMES Study Investigators, et al. Baseline characteristics and treatment response of patients from the Philippines in the CHIMES study. Int J Stroke. 2014;9:102–5.
Article
PubMed
Google Scholar
Harandi AA, Abolfazli R, Hatemian A, Ghragozlee K, Ghaffar-Pour M, Karimi M, et al. Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind placebo-controlled clinical trial. Stroke Res Treat. 2011;2011:721613.
CAS
PubMed
PubMed Central
Google Scholar
Young SH, Zhao Y, Koh A, Singh R, Chan BP, Chang HM, et al. Safety profile of MLC601 (Neuroaid) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine neuroaid efficacy on stroke recovery study. Cerebrovasc Dis. 2010;30(1):1–6.
Article
PubMed
Google Scholar
Chen CL, Venketasubramanian N, Lee CF, Wong KS, Bousser MG. Effects of MLC601 on early vascular events in patients after stroke: the CHIMES study. Stroke. 2013;44(12):3580–3.
Article
CAS
PubMed
Google Scholar
Kong KH, Wee SK, Ng CY, Chua K, Chan KF, Venketasubramanian N, et al. A double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional chinese medicine Neuroaid (MLC 601) in enhancing recovery after stroke (TIERS). Cerebrovasc Dis. 2009;28(5):514–21.
Article
CAS
PubMed
Google Scholar
Shahripour BR, Shamsaei G, Pakdaman H, Mojdinasab N, Nejad EM, Sajedi SA, et al. The effect of NeuroAiDTM (MLC601) on cerebral blood flow velocity in subjects’ post brain infarct in the middle cerebral artery territory. Eur J Intern Med. 2011;22(5):509–13.
Article
Google Scholar
Monthly Index of Medical Specialities. Malaysia. 2021. https://www.mims.com/malaysia/drug/info/neuroaid. Accessed 7 Sep 2021.
National Pharmaceutical Control Bureau, Ministry of Health Malaysia. Malaysian Variation Guideline for Natural (Traditional Medication and Homeopathy) and Health Care Supplement Products. 2016. https://www.npra.gov.my/index.php/en/guidelines-for-natural-products/1530-malaysian-variationguideline-for-natural-traditional-medicine-homeopathy-and-health-supplement-product-2016.html. Accessed 12 Oct 2016.
Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BPL, et al. Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery. Stroke. 2009;40(3):859–63.
Article
PubMed
Google Scholar
Ghandehari K, Mood ZI, Ebrahimzadeh S, Picard D, Zhang Y. NeuroAid (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia. Neural Regen Res. 2011;6(6):418–22.
CAS
Google Scholar
Venketasubramanian N, Moorakonda RB, Lu Q, Chen CLH. Frequency and clinical impact of serious adverse events on post-stroke recovery with NeuroAiD (MLC601) versus Placebo: the CHInese medicine neuroaid efficacy on stroke recovery study. Cerebrovasc Dis. 2020;49(2):192–9.
Article
PubMed
Google Scholar
Schwill S, Krug K, Peters-Klimm F, van Lieshout J, Laux G, Szecsenyi J, et al. Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction. BMC Fam Pract. 2018. https://doi.org/10.1186/s12875-018-0796-4.
Article
PubMed
PubMed Central
Google Scholar
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.
Article
Google Scholar
Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
Article
CAS
PubMed
Google Scholar
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
Article
CAS
PubMed
Google Scholar
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
Article
CAS
PubMed
Google Scholar
Liakoni E, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf. 2015;38(8):711–20.
Article
CAS
PubMed
Google Scholar
Maura G, Bardou M, Billionnet C, Weill A, Drouin J, Neumann A. Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. Sci Rep. 2020;10(1):1–11.
Article
Google Scholar
Rua J, Prata AR, Marques R, Silva R, Gomes B, Fraga J, et al. Carvedilol-induced liver injury, a rare cause of mixed hepatitis: a clinical case. GE Port J Gastroenterol. 2019;26(3):196–201.
Article
PubMed
Google Scholar
Philips C, Paramaguru R, Mahadevan P, Ravindranath J, Augustine P. Metoprolol-induced severe liver injury and successful management with therapeutic plasma exchange. Cureus. 2017. https://doi.org/10.7759/cureus.1209.
Article
PubMed
PubMed Central
Google Scholar
Alings M. Individualising anticoagulant therapy in atrial fibrillation patients. Arrhythm Electrophysiol Rev. 2016;5(2):102–9.
Article
PubMed
PubMed Central
Google Scholar
Mavilia MG, Pakala T, Molina M, Wu GY. Differentiating cystic liver lesions: a review of imaging modalities, diagnosis and management. J Clin Transl Hepatol. 2018;6(2):208–16.
Article
PubMed
PubMed Central
Google Scholar
Jing J, Teschke R. Traditional Chinese medicine and herb-induced liver injury: comparison with drug-induced liver injury. J Clin Transl Hepatol. 2018;6(1):57–68.
Article
PubMed
Google Scholar
Amadi CN, Orisakwe OE. Herb-induced liver injuries in developing nations: an update. Toxics. 2018;6(2):28.
Article
Google Scholar
Wu Q, Cai C, Guo P, Chen M, Wu X, Zhou J, et al. In silico Identification and mechanism exploration of hepatotoxic ingredients in traditional Chinese medicine. Front Pharmacol. 2019;10:1–15.
Article
Google Scholar
Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: Actual key issues and new encouraging steps. Front Pharmacol. 2015;6:1–40.
Article
CAS
Google Scholar